MedTrace Logo

Advanced Cross Linking for Low-grade Myopia

NCT03197272 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-12-11

No results posted yet for this study

Summary

To evaluate the improvement in myopic refractive error and the corneal endothelial safety with a corneal crosslinking treatment regimen for mild myopia. The treatment involves a 4-mm central treatment zone in high oxygen environment without corneal epithelial debridement.

Conditions

  • Myopia
  • Corneal Crosslinking

Interventions

PROCEDURE

PiXL

Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.

Sponsors & Collaborators

  • Glaukos Corporation

    collaborator INDUSTRY

  • Umeå University

    lead OTHER

Principal Investigators

  • Anders Behndig, MD, PhD · Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-21
Primary Completion
2020-10-31
Completion
2020-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03197272 on ClinicalTrials.gov